myelodysplastic syndrome with excess blasts-2
myelodysplastic syndrome with excess blasts-2
Explore linked clinical trials. Standard reference: MONDO:00150415 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-09-22 | NCT03839771 | |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, leukemia, myelodysplastic syndrome with excess blasts-1, myelodysplastic syndrome with excess blasts-2, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, primary myelofibrosis, therapy related acute myeloid leukemia and myelodysplastic syndrome | Active, not recruiting | Phase 1 | 2026-09-18 | NCT02530034 | |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-08-26 | NCT03850574 | |
| BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2025-07-18 | NCT05703542 | |
| A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2024-12-17 | NCT04027309 |